Eisai Announces Real-World Evidence on the Clinical Effectiveness of LENVIMA® (lenvatinib) Monotherapy for the Treatment of Patients with Radioiodine-Refractory Differentiated Thyroid Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Eisai announced today results from a post-hoc analysis of three randomized, pivotal, Phase 3 studies (EMBRACE trial/Study 305, Study 301, and.
Eisai Announces Publication of Post Hoc Analysis Data of LENVIMA® (lenvatinib) from Phase 3 SELECT Trial in Certain Patients with Differentiated Thyroid Cancer in the European Journal of Cancer
News provided by
Share this article
published the results from a post hoc analysis of the Phase 3 SELECT study evaluating the impact of lung metastases on overall survival (OS) in patients with locally recurrent or metastatic, progressive radioiodine-refractory differentiated thyroid cancer (RAI-refractory DTC) who were treated with LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai. These data were originally presented at the European Society for Medical Oncology (ESMO) Annual Meeting in September 2019.
Eisai Announces Publication of Post Hoc Analysis Data of LENVIMA® (lenvatinib) from Phase 3 SELECT Trial in Certain Patients with Differentiated Thyroid Cancer in the European Journal of Cancer prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.